Target Name: MIR4482
NCBI ID: G100616323
Review Report on MIR4482 Target / Biomarker Content of Review Report on MIR4482 Target / Biomarker
MIR4482
Other Name(s): microRNA 4482 | hsa-mir-4482 | MicroRNA 4482 | hsa-miR-4482-5p | hsa-mir-4482-1 | MicroRNA 4482-1 | hsa-miR-4482-3p | MIR4482-1

MIR4482: A Potential Drug Target and Biomarker for Obesity

Obesity is a significant public health issue, with over 20% of adults worldwide classified as obese or overweight. The increasing prevalence of obesity is associated with an increased risk of various chronic diseases, such as cardiovascular disease, diabetes, and certain types of cancer. As such, identifying potential drug targets and biomarkers for obesity is of great importance. In this article, we will focus on MIR4482, a potential drug target and biomarker for obesity.

MIR4482 is a gene that encodes a protein known as mir4482. The Mir gene is a family of transmembrane proteins that play a crucial role in the regulation of energy metabolism and cell growth. Mir4482 is expressed in various tissues and cells, including adipocytes, muscle fibers, and brain cells. It has been shown to be involved in the regulation of lipid metabolism, which is a key aspect of obesity development.

Studies have suggested that MIR4482 may be a potential drug target for obesity. Obesity is often associated with alterations in the balance of lipid metabolism, with an increase in plasma triglycerides and cholesterol levels. MIR4482 has been shown to regulate lipid metabolism by modulating the expression of genes involved in lipid synthesis and degradation. For instance, MIR4482 has been shown to enhance the expression of genes involved in triacylglycerol (TAG) metabolism, such as ATG4 and ABCC9, which are critical for the synthesis and degradation of triacylglycerols.

In addition to its role in lipid metabolism, MIR4482 has also been shown to play a role in the regulation of cellular energy metabolism. It has been shown to promote the translation of genes involved in cellular energy metabolism, such as the succinyl-CoA synthetase gene (SCS) and the electron transport chain (ETS). These genes are involved in the citric acid cycle, also known as the Krebs cycle or TCA cycle, which is a critical pathway for cellular energy production.

MIR4482 has also been shown to be involved in the regulation of cellular signaling pathways. It has been shown to interact with several signaling pathways, including the TGF-β pathway and the NF-kappa-B pathway. These signaling pathways are involved in the regulation of cellular processes such as cell growth, differentiation, and inflammation.

Given its involvement in various biological processes, MIR4482 is a promising candidate for targeting in obesity. Studies have shown that MIR4482 has been expressed in human obese tissues and is involved in the regulation of lipid metabolism, cellular energy metabolism, and cellular signaling pathways.

In addition to its potential therapeutic applications, MIR4482 is also a potential biomarker for obesity. The Mir gene is widely expressed in various tissues and cells, including fat cells and muscle fibers. Therefore, measuring the expression of MIR4482 may be a useful diagnostic tool for obesity.

Furthermore, MIR4482 has been shown to be involved in the regulation of obesity-related behaviors, such as food intake and energy expenditure. Obesity is often associated with altered patterns of energy intake and energy expenditure, which can contribute to the maintenance of obesity. MIR4482 has been shown to regulate the expression of genes involved in energy metabolism and calorie homeostasis, such as the PPAR伪 gene and the UCP2 gene.

In conclusion, MIR4482 is a promising candidate for targeting in obesity. Its involvement in lipid metabolism, cellular energy metabolism, and cellular signaling pathways makes it a promising target for the development of anti-obesity drugs. Furthermore, MIR4482 is also a potential biomarker for obesity, which could be used for the diagnosis and monitoring of obesity. Further studies are needed to confirm its potential as a drug target and biomarker for obesity.

Protein Name: MicroRNA 4482

The "MIR4482 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR4482 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR4483 | MIR4484 | MIR4485 | MIR4486 | MIR4487 | MIR4488 | MIR4489 | MIR4491 | MIR4492 | MIR4493 | MIR4496 | MIR4497 | MIR4498 | MIR4499 | MIR449A | MIR449B | MIR449C | MIR4500 | MIR4500HG | MIR4501 | MIR4504 | MIR4505 | MIR4506 | MIR4507 | MIR4508 | MIR4509-1 | MIR4509-2 | MIR4509-3 | MIR450A1 | MIR450A2 | MIR450B | MIR4510 | MIR4511 | MIR4512 | MIR4513 | MIR4514 | MIR4516 | MIR4519 | MIR451A | MIR451B | MIR452 | MIR4520-1 | MIR4520-2 | MIR4521 | MIR4524A | MIR4524B | MIR4525 | MIR4526 | MIR4527 | MIR4527HG | MIR4529 | MIR4530 | MIR4531 | MIR4533 | MIR4534 | MIR4535 | MIR4536-1 | MIR4536-2 | MIR4537 | MIR4538 | MIR4539 | MIR454 | MIR4540 | MIR455 | MIR4632 | MIR4633 | MIR4634 | MIR4635 | MIR4638 | MIR4639 | MIR4640 | MIR4641 | MIR4642 | MIR4644 | MIR4645 | MIR4646 | MIR4647 | MIR4648 | MIR4649 | MIR4650-1 | MIR4650-2 | MIR4651 | MIR4652 | MIR4653 | MIR4655 | MIR4656 | MIR4657 | MIR4658 | MIR4659A | MIR4659B | MIR466 | MIR4660 | MIR4661 | MIR4662A | MIR4663 | MIR4664 | MIR4665 | MIR4666A | MIR4666B | MIR4667